BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20058065)

  • 1. Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy.
    Blaes AH; Gaillard P; Peterson BA; Yee D; Virnig B
    Breast Cancer Res Treat; 2010 Jul; 122(2):585-90. PubMed ID: 20058065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of routine pre-chemotherapy screening with cardiac gated blood pool scan for patients at low risk of anthracycline toxicity.
    Chia PL; Chiang K; Snyder R; Dowling A
    J Oncol Pharm Pract; 2018 Jun; 24(4):264-271. PubMed ID: 29284360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy.
    Blaes AH; Rehman A; Vock DM; Luo X; Menge M; Yee D; Missov E; Duprez D
    Vasc Health Risk Manag; 2015; 11():591-4. PubMed ID: 26648730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity.
    Boucek RJ; Steele A; Miracle A; Atkinson J
    Cardiovasc Toxicol; 2003; 3(4):319-29. PubMed ID: 14734829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
    Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
    Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.
    Gujral DM; Lloyd G; Bhattacharyya S
    Breast; 2018 Feb; 37():64-71. PubMed ID: 29101824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
    Yamaguchi N; Fujii T; Aoi S; Kozuch PS; Hortobagyi GN; Blum RH
    Eur J Cancer; 2015 Nov; 51(16):2314-20. PubMed ID: 26343314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
    Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
    J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.
    Farolfi A; Melegari E; Aquilina M; Scarpi E; Ibrahim T; Maltoni R; Sarti S; Cecconetto L; Pietri E; Ferrario C; Fedeli A; Faedi M; Nanni O; Frassineti GL; Amadori D; Rocca A
    Heart; 2013 May; 99(9):634-9. PubMed ID: 23349345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
    Skubitz KM; Blaes AH; Konety SH; Francis GS
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical value of echocardiography and acoustic cardiography to monitor patients undergoing anthracycline chemotherapy.
    Toggweiler S; Odermatt Y; Brauchlin A; Zander T; Müller A; Zuber M; Winterhalder R; Erne P
    Clin Cardiol; 2013 Apr; 36(4):201-6. PubMed ID: 23161530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.
    Brown TR; Vijarnsorn C; Potts J; Milner R; Sandor GG; Fryer C
    Pediatr Blood Cancer; 2013 May; 60(5):842-8. PubMed ID: 23382019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.
    Uyar D; Kulp B; Peterson G; Zanotti K; Markman M; Belinson J
    Gynecol Oncol; 2004 Jul; 94(1):147-51. PubMed ID: 15262133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Necessity of routine cardiac evaluation in patients receiving pegylated liposomal doxorubicin for gynecologic cancer.
    Dioun SM; Vilardo N; Goldberg GL; Gressel GM
    Gynecol Oncol; 2019 Nov; 155(2):301-304. PubMed ID: 31575390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors.
    Brockstein BE; Smiley C; Al-Sadir J; Williams SF
    Bone Marrow Transplant; 2000 Apr; 25(8):885-94. PubMed ID: 10808211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial.
    Gupta V; Kumar Singh S; Agrawal V; Bali Singh T
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27308. PubMed ID: 30009543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation.
    Zambetti M; Moliterni A; Materazzo C; Stefanelli M; Cipriani S; Valagussa P; Bonadonna G; Gianni L
    J Clin Oncol; 2001 Jan; 19(1):37-43. PubMed ID: 11134193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines.
    Dranitsaris G; Rayson D; Vincent M; Chang J; Gelmon K; Sandor D; Reardon G
    Breast Cancer Res Treat; 2008 Feb; 107(3):443-50. PubMed ID: 17978870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective comparison of cardiac magnetic resonance imaging and radionuclide ventriculography in the assessment of cardiac function in patients treated with anthracycline-based chemotherapy.
    Sipola P; Vanninen E; Jantunen E; Nousiainen T; Kiviniemi M; Hartikainen J; Kuittinen T
    Nucl Med Commun; 2012 Jan; 33(1):51-9. PubMed ID: 22044862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.